Last reviewed · How we verify
NCT03784508: PREDI-BAR
Identification of Biomarkers of Response After Bariatric Surgery in Morbidly Obese Patients
trial in Morbid Obesity in 200 participants. Status unknown.
31 December 2021
Quick facts
| Lead sponsor | Hospital Universitari Vall d'Hebron Research Institute |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 1 April 2018 |
| Primary completion | 31 December 2021 |
| Estimated completion | 1 April 2022 |
| Sites | 1 location across Spain |
Conditions studied
- Morbid Obesity — all drugs for Morbid Obesity →
Sponsor
Hospital Universitari Vall d'Hebron Research Institute
Who can join
Adults 18 to 65, any sex, with Morbid Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The prevalence of obesity in Spain is about 21.6%. The discouraging results provided by dietary treatment, together with the lack of funding for pharmacological treatment, have led to the progressive use of bariatric surgery (CB). Besides weight loss, CB associates a beneficial effect on metabolic comorbidities. However, 25-30% of operated patients present a weight response considered inappropriate, they do not resolve their comorbidities and/or present a weight-regain shortly after surgery. Therefore, predictive strategies are necessary to allow a correct selection of obese patients who are candidates for CB. The main hypothesis of the study is that various factors such as psychopathological profile, body composition and metabolic alterations related to morbid obesity can influence the response to bariatric surgery.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03784508
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Morbid Obesity
Currently open trials in the same condition.
- NCT06689241 — Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery · NA · recruiting
- NCT06413264 — Ultrasonography Guided Pneumoperitoneum for Laparoscopic Surgery in Morbidly Obese Patients · NA · recruiting
- NCT07289555 — Tailored Stapled SADI-S: Initial Report and Preliminary Results · NA · recruiting
- NCT07263269 — Comparing Dumping Symptoms and Quality of Life 6 Months After Sleeve Gastrectomy With or Without Transit Bipartition in · NA · active not recruiting
- NCT06293703 — Effect of Limb Length Ratio on Roux-en-Y Gastric Bypass Outcomes (CLIMB II Study) · NA · recruiting
Other Hospital Universitari Vall d'Hebron Research Institute trials
Trials by the same sponsor.
- NCT07519343 — Migraine and Endometriosis: The FEMININE Study · not yet recruiting
- NCT07509541 — Hemodynamic and Respiratory Instability During Percutaneous Pulmonary Thrombectomy · not yet recruiting
- NCT07456280 — Evaluation of the Non-invasive Electrocardiographic Monitoring Strategy Associated With Early Discharge in Patients With · NA · not yet recruiting
- NCT07281911 — Early Biological and Mechanical Profiling in Sepsis-Associated ARDS · not yet recruiting
- NCT07430501 — Using Digital Twin Technology and Clinical Decision Support Systems to Improve the Early Detection, Personalised Treatme · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03784508 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital Universitari Vall d'Hebron Research Institute
- Last refreshed: 10 February 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03784508.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing